Artivion (NYSE:AORT) executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.
CEO Pat Mackin said Art
What Happened? Shares of medical device company Artivion (NYSE:AORT) fell 26.8% in the afternoon session after it reported first-quarter results that missed ...
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the o...
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the o...
Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after market close. Here’s what you need to know. Artivion missed analys...
Over the last six months, Artivion’s shares have sunk to $37.03, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 3.9% gain. This was...
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...
What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ...
Check out the companies making headlines yesterday: Levi's (NYSE:LEVI): Denim clothing company Levi's (NYSE:LEVI) rose by 2.8% on Monday after investor optim...
What Happened? Shares of medical device company Artivion (NYSE:AORT) fell 2.1% in the afternoon session after a proposed 2027 federal budget revealed signifi...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in t...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand for stent grafts, which grew 36% year-over-year, and continued gains from the On-X mechanical heart valve, which benefited from newly published clinical data. CEO Pat Mackin noted, “Growth was driven by our continued global market share gains and early traction in our new $100 million U.S. market opportunity unlocked by recently published data.” However, tissue processing revenue remained subdued, reflecting lingering impacts from a prior cybersecurity incident, while BioGlue sales were flat due to distributor stocking variability.
Shares of medical device company Artivion (NYSE:AORT)
fell 5.8% in the morning session after the company reported mixed fourth-quarter 2025 financial results, with revenues falling short of analyst expectations.
Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year revenue guidance of $495 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was in line with analysts’ consensus estimates.
Medical device company Artivion (NYSE:AORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year revenue guidance of $495 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was in line with analysts’ consensus estimates.
